These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 37875792)
21. Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19. Hamilton DO; Main-Ian A; Tebbutt J; Thrasher M; Waite A; Welters I Thromb J; 2021 Nov; 19(1):87. PubMed ID: 34781984 [TBL] [Abstract][Full Text] [Related]
22. The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. Di Micco P; Tufano A; Cardillo G; Imbalzano E; Amitrano M; Lodigiani C; Bellizzi A; Camporese G; Cavalli A; De Stefano C; Russo V; Voza A; Perrella A; Prandoni P Viruses; 2021 Aug; 13(9):. PubMed ID: 34578301 [TBL] [Abstract][Full Text] [Related]
23. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617 [TBL] [Abstract][Full Text] [Related]
24. Venous Thromboembolism Prophylaxis in Low Body Weight Critically Ill Patients. Knox H; Edwin SB; Giuliano C; Paxton RA J Intensive Care Med; 2024 May; 39(5):493-498. PubMed ID: 38111295 [TBL] [Abstract][Full Text] [Related]
25. Unfractionated heparin versus enoxaparin for venous thromboembolism prophylaxis in intensive care units: a propensity score adjusted analysis. Samuel S; Li W; Dunn K; Cortes J; Nguyen T; Moussa D; Kumar A; Dao T; Beeson J; Choi HA; McCullough LD J Thromb Thrombolysis; 2023 May; 55(4):617-625. PubMed ID: 37029256 [TBL] [Abstract][Full Text] [Related]
26. Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Zwicker JI; Roopkumar J; Puligandla M; Schlechter BL; Sharda AV; Peereboom D; Joyce R; Bockorny B; Neuberg D; Bauer KA; Khorana AA Blood Adv; 2020 May; 4(10):2254-2260. PubMed ID: 32442298 [TBL] [Abstract][Full Text] [Related]
27. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma. Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333 [TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
29. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA; J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258 [TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients. Mason SW; Barber A; Jones E; Chen SL; Moll S; Northam K Am J Med; 2020 Jun; 133(6):e249-e259. PubMed ID: 31862336 [TBL] [Abstract][Full Text] [Related]
31. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ; Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876 [TBL] [Abstract][Full Text] [Related]
32. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients. Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment. Chamoun N; Ghanem H; Hachem A; Hariri E; Lteif C; Mansour H; Dimassi H; Zalloum R; Ghanem G BMC Pharmacol Toxicol; 2019 May; 20(1):27. PubMed ID: 31064405 [TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W; N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811 [TBL] [Abstract][Full Text] [Related]
36. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD; Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900 [TBL] [Abstract][Full Text] [Related]
37. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129 [TBL] [Abstract][Full Text] [Related]
38. Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. Pannucci CJ; Fleming KI; Bertolaccini CB; Prazak AM; Huang LC; Pickron TB JAMA Surg; 2019 Aug; 154(8):697-704. PubMed ID: 31116389 [TBL] [Abstract][Full Text] [Related]
39. Association of Changes in Antithrombin Activity Over Time With Responsiveness to Enoxaparin Prophylaxis and Risk of Trauma-Related Venous Thromboembolism. Vincent LE; Talanker MM; Butler DD; Zhang X; Podbielski JM; Wang YW; Chen-Goodspeed A; Hernandez Gonzalez SL; Fox EE; Cotton BA; Wade CE; Cardenas JC JAMA Surg; 2022 Aug; 157(8):713-721. PubMed ID: 35731524 [TBL] [Abstract][Full Text] [Related]
40. Adverse outcomes of anticoagulant use among hospitalized patients with chronic kidney disease: a comparison of the rates of major bleeding events between unfractionated heparin and enoxaparin. Saheb Sharif-Askari F; Syed Sulaiman SA; Saheb Sharif-Askari N; Al Sayed Hussain A; Railey MJ PLoS One; 2014; 9(9):e106517. PubMed ID: 25181525 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]